Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
Division of Cardiology, "IRCCS Sacro Cuore - Don Calabria" Hospital, Negrar (VR), Italy.
Diabetes Metab. 2020 Apr;46(2):150-157. doi: 10.1016/j.diabet.2019.07.006. Epub 2019 Aug 3.
Recent prospective studies have identified distinct plasma ceramides as strong predictors of major adverse cardiovascular events in patients with established or suspected coronary artery disease (CAD). Currently, it is uncertain whether higher levels of distinct plasma ceramides are associated with greater angiographic severity of coronary-artery stenoses in this patient population.
We measured six previously identified high-risk plasma ceramide species [Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/20:0), Cer(d18:1/22:0), Cer(d18:1/24:0) and Cer(d18:1/24:1)] in 167 consecutive patients with established or suspected CAD, who underwent urgent or elective coronary angiography.
Approximately 77% of patients had a significant stenosis (≥50%) in one or more of the main coronary arteries, the majority of whom (∼60%) had a significant stenosis in the left anterior descending (LAD) artery. Of the six measured plasma ceramides, higher levels of plasma Cer(d18:1/20:0) (adjusted-odds ratio 1.39, 95%CI 1.0-1.99), Cer(d18:1/22:0) (adjusted-odds ratio 1.57, 95%CI 1.08-2.29) and Cer(d18:1/24:0) (adjusted-odds ratio 1.59, 95%CI 1.08-2.32) were significantly associated with the presence of LAD stenosis≥50%, after adjustment for age, sex, smoking, pre-existing CAD, hypertension, diabetes, dyslipidaemia, lipid-lowering therapy, estimated glomerular filtration rate and plasma C-reactive protein levels. Almost identical results were found even after excluding patients (n=15) with acute ST-elevation myocardial infarction. Similar results were also found when patients were categorized according to the Gensini severity score.
Our cross-sectional study shows for the first time that higher levels of specific plasma ceramides are independently associated with a greater severity of coronary-artery stenoses in the LAD artery in patients who had suspected or established CAD.
最近的前瞻性研究已经确定了不同的血浆神经酰胺作为已确诊或疑似冠心病(CAD)患者发生主要不良心血管事件的强有力预测因子。目前,尚不确定在这一患者群体中,不同的血浆神经酰胺水平是否与冠状动脉狭窄的血管造影严重程度更大相关。
我们在 167 例已确诊或疑似 CAD 的连续患者中测量了 6 种先前确定的高风险血浆神经酰胺种类[Cer(d18:1/16:0)、Cer(d18:1/18:0)、Cer(d18:1/20:0)、Cer(d18:1/22:0)、Cer(d18:1/24:0)和 Cer(d18:1/24:1)],这些患者接受了紧急或选择性冠状动脉造影。
约 77%的患者有一条或多条主要冠状动脉的显著狭窄(≥50%),其中大多数(约 60%)的左前降支(LAD)有显著狭窄。在测量的 6 种血浆神经酰胺中,较高的血浆 Cer(d18:1/20:0)(调整后比值比 1.39,95%CI 1.0-1.99)、Cer(d18:1/22:0)(调整后比值比 1.57,95%CI 1.08-2.29)和 Cer(d18:1/24:0)(调整后比值比 1.59,95%CI 1.08-2.32)水平与 LAD 狭窄≥50%显著相关,校正年龄、性别、吸烟、既往 CAD、高血压、糖尿病、血脂异常、降脂治疗、估计肾小球滤过率和血浆 C 反应蛋白水平后。即使排除了 15 例急性 ST 段抬高型心肌梗死患者(n=15),也得到了几乎相同的结果。当根据 Gensini 严重程度评分对患者进行分类时,也得到了类似的结果。
我们的横断面研究首次表明,在疑似或确诊 CAD 的患者中,特定血浆神经酰胺水平较高与 LAD 动脉冠状动脉狭窄严重程度独立相关。